tranScrip is providing support as Synairgen confirms commencement of dosing in a trial of SNG001 in COVID-19

tranScrip (www.transcrip-partners.com) is delighted to be supporting Synairgen with their first patient dosing in a trial of SNG001 in COVID-19.

tranScrip's support in this important endeavour is a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.

Dr Marcin Mankowski, Deputy Managing Partner and Head of tranScrip’s ID Team, commented: “tranScrip has collaborated with Synairgen for many years, supporting the development of SNG001 to address an important medical need in the treatment of viral exacerbations of asthma and COPD. With the COVID-19 pandemic, our ID, respiratory, PV and regulatory affairs experts continue working closely with the Synairgen team on this unprecedented programme. We will be looking forward to the results of the study, which could offer an important treatment option for patients suffering from COVID-19 illness.”

tranScrip’s team of experts and supporting staff are passionate about bringing innovative and essential medicines to the market place and patients. We are committed to maintaining business continuity and supporting our clients during these challenging times and have capacity to support where needed.

If you need us, across any aspect of drug development, from translational medicine through to registration and lifecycle management, we are here to help to ensure your business can continue successfully. Contact paul.branthwaite@transcrip-partners.com.